All In Biotech

Drug Trial Radar · NCT04326374

Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency

The Efficacy, Safety and Tolerability of TransCon hGH Administered Weekly Versus Daily hGH in Prepubertal Children With Growth Hormone Deficiency: a Randomized, Open-lable, Active-controlled, Parallel-group Study in China

Last checked: Nov 20, 2026Latest source record: Mar 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Dec 30, 2019

Primary completion

Apr 2022

Study completion Apr 2022

Sponsor

Sponsor type
Industry
Collaborators
Ascendis Pharma A/S
First posted
Mar 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is conducted in China only. The purpose is to demonstrate the efficacy and safety of once weekly dosing of TransCon hGH, a long-acting growth hormone product, compare to once-daily dosing of human growth hormone (hGH) after 52 weeks of treatment in prepubertal children with growth hormone deficiency (GHD).

Conditions

  • Growth Hormone Deficiency
  • Endocrine System Diseases
  • Hormones
  • Pituitary Diseases
  • Pituitary Disease, Anterior

Interventions

  • TransCon hGHDrug

    Once weekly subcutaneous injection

  • daily hGHDrug

    Once daily subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized height velocity(AHV) at Week 52Time frame: 52 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.